News
Article
Updates on EXG102 and EXG202 for wet AMD from Exegenesis Bio
Author(s):
Key Takeaways
- EXG102 and EXG202 are gene therapies for wet AMD, with EXG202 offering less invasive intravitreal injection and improved retinal transduction efficiency.
- Exegenesis Bio's strategy targets multiple neovascular pathways and uses a proprietary capsid for efficient delivery to photoreceptors and retinal pigment epithelium.
EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.
(Image Credit: AdobeStock/RFBSIP)
Exegenesis Bio provided an update on the company’s treatment candidates for wet age-related macular degeneration (wet AMD).
EXG102 is an investigational gene therapy for wet AMD that is administered by subretinal injection. EXG202, a next generation version, incorporates the same genetic cargo as EXG102, but is delivered to deep retinal cells by a highly-specific ocular capsid that enables administration by intravitreal injection, a less invasive, non-surgical approach. EXG202 has demonstrated a 3 to 5-fold increase in retinal transduction efficiency over currently known ocular-specific capsids in a non-human primate study.1
Zhenhua Wu, CEO of Exegenesis Bio spoke on these candidates in the company’s press release1, saying, “This is another milestone in our journey to become a truly Global Gene Therapy company. We recently shared updates on our other clinical programs and technology platforms at the European Society for Gene and Cell Therapy meeting, including updates on EXG102/202, a clinical stage gene therapy for wet Age-Related Macular Degeneration”
He continued, “Our unique approach to wet AMD is built on three pillars: (1) targeting multiple pathways involved in neovascular disease, including VEGF subtypes A, B, C, D and Angiopoietin 2; (2) packaging our cargo in a proprietary capsid that targets photoreceptors and retinal pigment epithelium more efficiently, and (3) administering the treatment by intravitreal injection, a safe, non-surgical procedure. We believe this will result in a "Best-In-Class" treatment for wet AMD and other ocular diseases. We are currently conducting clinical trials in USA and China and hope to share further data in the coming months.”1
Further updates from Exegenesis Bio on Fabry Disease, wet AMD, Spinal Muscular Atrophy, and Muscle Tropic Capsid programs are expected during JP Morgan week in San Francisco, Jan 13-16, 2025.1
Reference:
US FDA Grants Orphan Drug Designation to EXG110, a Novel Gene Therapy for Fabry Disease. Exegenesis Bio. December 3, 2024. Accessed December 9, 2024. https://www.morningstar.com/news/business-wire/20241203974744/us-fda-grants-orphan-drug-designation-to-exg110-a-novel-gene-therapy-for-fabry-disease
